Featured projects

  • A phase II trial of cabozantinib for patients with hepatocellular carcinoma in sorafenib intolerant (ACTION trial)

    Funder: Fundació Clínic per a la Recerca Biomèdica. .
    Duration: 25/03/2019
  • A multicentrer phase II study of Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma after first-line treatment (GOING trial)

    Funder: Fundació Clínic per a la Recerca Biomèdica. .
    Duration: 12/03/2019
  • Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cancer de higádo (PI18/00358)

    Principal investigator: María Reig.
    Funder: Institut d'Investigacions Biomèdiques August Pi i Sunyer (August Pi i Sunyer Biomedical Research Institute - IDIBAPS (Sede); Instituto de Salud Carlos III .
    Duration: 01/01/2019 - 01/01/2021
  • A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHAFETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) ADP-0033-00

    Funder: Adaptimmune Therapeutics .
    Duration: 01/09/2018
  • A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

    Principal investigator: Jordi Bruix Tudo.
    Code: ADP-0033-001.
    Duration: 01/01/2018 - 31/12/2033
  • Multicenter, open label single arm safety study and the antitumor efficacy of Nivolumab after Selective Internal Radiation Therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional th

    Funder: Clínica Universitaria de Navarra .
    Duration: 01/01/2018
  • Analysis of potential changes in antitumor immune activity in patients with hepatocellular carcinoma after C virus erradication with direct antiviral agents (GLD/00095)

    Principal investigator: Maria Reig.
    Funder: Clinica Universitaria de Navarra y Hosptial Clinic de Barcelona (Sede); Gilead Sciences, S.L. .
    Duration: 01/01/2017
  • A Randomized, Open label, Multicenter Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)

    Funder: AstraZeneca Farmacéutica Spain .
    Duration: 01/01/2017